Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for andrea pritsch
Your search for Andrea Prutsch retrieved no results
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.
Kroidl I, Winter S, Rubio-Acero R, Bakuli A, Geldmacher C, Eser TM, Déak F, Horn S, Zielke A, Ahmed MIM, Diepers P, Guggenbühl J, Frese J, Bruger J, Puchinger K, Reich J, Falk P, Markgraf A, Fensterseifer H, Paunovic I, Thomschke A, Pritsch M, Riess F, Saathoff E, Hoelscher M, Olbrich L, Castelletti N, Wieser A; KoCo19/ORCHESTRA Study Group. Kroidl I, et al. Virol J. 2023 Sep 1;20(1):200. doi: 10.1186/s12985-023-02167-z. Virol J. 2023. PMID: 37658454 Free PMC article.
MR imaging in children with transverse myelitis and acquired demyelinating syndromes.
El Naggar I, Cleaveland R, Wendel EM, Bertolini A, Schanda K, Karenfort M, Thiels C, Della Marina A, Schimmel M, Leiz S, Lechner C, Baumann M, Reindl M, Wegener-Panzer A, Rostásy K; on-behalf-of-the-BIOMARKER-Study-Group. El Naggar I, et al. Mult Scler Relat Disord. 2022 Nov;67:104068. doi: 10.1016/j.msard.2022.104068. Epub 2022 Jul 22. Mult Scler Relat Disord. 2022. PMID: 35933757
Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).
Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. Dietz A, et al. Eur Arch Otorhinolaryngol. 2009 Aug;266(8):1291-300. doi: 10.1007/s00405-008-0846-y. Epub 2008 Oct 30. Eur Arch Otorhinolaryngol. 2009. PMID: 18972123 Clinical Trial.